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Respiratory tract infections, NSAIDs and acute myocardial infarction: is understanding interaction 
between risk factors the key to personalising prevention?  
 
Acute respiratory infections are increasingly recognised as triggers of acute cardiovascular events1. 
Observational studies using large electronic healthcare databases have shown an approximately two 
to five-fold transient increase in the risk of acute myocardial infarction, stroke and other thrombotic 
events such as deep venous thrombosis after acute respiratory infection (ARI)2–4. Although the 
coding of ARI in these studies is frequently based on clinical, rather than microbiological criteria, 
evidence that some specific infections trigger vascular events comes indirectly from vaccine trials. 
Meta-analysis of randomized controlled trials of influenza vaccine in patients with existing 
cardiovascular disease showed a reduced risk of major adverse cardiovascular outcomes at one 
year5.  For pneumococcal vaccine, meta-analyses of observational studies suggest a small protective 
effect against cardiovascular events in people aged >65 years6,7, but trial evidence is lacking. In 
people who develop ARI, there remain unanswered questions about how different ARI treatments 
might modulate vascular risk.  
 
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to reduce pain, fever and 
inflammation associated with acute infections as well as symptoms of chronic musculoskeletal and 
other inflammatory conditions. While the risk of gastrointestinal haemorrhage associated with these 
drugs has long been recognised, in recent years attention has focussed on adverse cardiovascular 
effects. Initially, concerns about increased risk of acute cardiovascular events arose when the new 
class selective COX II inhibitors, with lower risks of gastrointestinal bleeding, were introduced8–10. 
However, a growing body of evidence has now established that risks of vascular events are increased 
by traditional non-selective NSAIDs, notably diclofenac11. The US Food and Drug Administration 
(FDA) recommended that the selective COX-2 inhibitors rofecoxib and valdecoxib be removed from 
the market in 2004 and 200512, and recently issued a black box warning that NSAIDs can cause heart 
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attacks13. In the UK, NICE recommends cautious prescription of NSAIDs based on assessing an 
individual’s risk factors such as history of cardiovascular and gastrointestinal illness, using the lowest 
effective dose for the shortest duration necessary to control symptoms and opting for naproxen or 
low-dose ibuprofen for their more favourable thrombotic cardiovascular safety profile14.  
Nevertheless, some NSAIDs such as ibuprofen are widely available over the counter, and in the US, 
NSAIDS are reportedly taken at least once per week by 50% of people over the age of 65 years15.  
 
In this issue of the Journal of Infectious Diseases, Wen and colleagues provide evidence for a dual 
effect of acute respiratory infection and NSAIDs on myocardial infarction risk in a case crossover 
study of 9,793 patients from Taiwan16. Using comprehensive claims data over a 7-year period from 
the National Health Research Insurance Database, which covers ~99% of the population, they 
showed that acute respiratory infections treated with NSAIDs had a stronger association with AMI 
than ARIs not treated with NSAIDs or NSAID treatment alone. A series of sensitivity analyses 
strengthened the validity of the results and reduced the risk of bias due to inappropriate control 
time window selection. This study represents an important step towards understanding the 
interaction between transient, non-traditional AMI risk factors.  
 
The effects of NSAIDs are largely mediated through inhibition of cyclooxygenase (COX), which 
prevents the conversion of arachidonic acid into its biologically active derivatives17 and thus 
profoundly alters prostaglandin homeostasis15. Different NSAIDs have different activity profiles 
against the COX-1 and COX-2 isoforms. It is likely that the cardiovascular risk associated with non-
selective and COX-2 inhibitors results from various mechanisms including altering the balance of 
thromboxane and prostacyclin leading to increased platelet aggregation and vasoconstriction, as 
well as fluid and sodium retention17. Acute respiratory infections induce a range of haemodynamic, 
pro-coagulant and pro-inflammatory effects that contribute to the risk of cardiac complications18.  It 
is certainly plausible that interaction between these deleterious mechanisms may in part explain the 
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greater risk of AMI seen in ARIs treated with NSAIDs compared to untreated ARIs or NSAID use 
alone. 
 
The case crossover design has the major advantage of eliminating the effect of fixed between-
person confounders as each individual serves as their own control over time.19 Specifically, in the 
present study the effect of exposure to ARI and NSAIDs on AMI was compared within a ‘case’ period 
and a ‘control’ period for each patient. The authors also adjusted for time-varying confounding due 
to discordant concomitant medication use in their multivariable analysis.  One potential limitation of 
the chosen design, however, which was noted by the authors in the discussion, is the risk of 
confounding by indication20. This is the situation in which the clinical indication for prescribing drugs 
such as NSAIDs (e.g. severity of ARI, fever and pain), also affects the risk of experiencing the 
outcome (here, AMI). Although a sensitivity analysis to investigate the effect of NSAID use during 
different types of ARI showed that AMI risk was higher with NSAID use for influenza-related ARIs, 
other ARIs and no ARI, the limited data on illness severity available in health insurance claims 
databases made this impossible to evaluate further. The largest effect size was seen for parenteral 
NSAID use in the context of ARI, which again might suggest a more severe underlying illness. Both 
improving data availability on infection severity and considering the use of methods such as 
propensity scores to reduce bias21 will be important for future research in this area.  
 
An important unanswered question that will inform clinical practice relates to the differential effects 
of specific NSAIDs used for symptomatic ARI relief on cardiovascular risk.  In a supplementary 
analysis, Wen and colleagues stratified by type of NSAID to investigate separately the effects of 
diclofenac, mefenamic acid, the selective COX-2 inhibitors used in Taiwan (celecoxib, rofecoxib and 
etorcoxib) and using multiple non-parenteral NSAIDs during an ARI. No data were available on the 
effects of naproxen or ibuprofen – the two NSAIDs currently considered to have the most favourable 
thrombotic cardiovascular safety profiles14.  Although minor differences in effect size were seen 
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between different non-parenteral NSAIDs, the overlapping confidence intervals and relatively small 
sample size in each stratum make these results difficult to interpret. While it is mechanistically 
plausible that, in the context of ARI as in other settings, selective COX-2 inhibitors may induce 
greater cardiac risk than some non-selective agents, this is not yet evident from available data.  
 
In moving from considering ARI symptomatic treatments to designing targeted prevention 
strategies, it will be necessary to understand the relative contribution that different respiratory 
organisms make to vascular risk.  In the present study, ARI episodes were based on codes for out-
patient visits with clinically-diagnosed infection rather than laboratory-confirmed organisms, but 
authors note that previously a good correlation (0.71) has been shown between the codes used and 
the presence of respiratory pathogens. Other approaches that have been used to infer the causative 
organism from medical records data include using timing of an infection relative to specific organism 
circulation in the community, the influenza vaccination status of the patient and codes used to 
classify an illness22, but this is not an exact science. Basing studies using laboratory indices of 
infection will help to inform the use of targeted vaccinations to reduce vascular risk.  While influenza 
and pneumococcal vaccines are currently recommended for some groups at high risk of 
cardiovascular complications including the over 65s and people with existing heart disease23, better 
understanding the organisms involved will improve mechanistic understanding, help to inform 
clinical trials and design of preventive and therapeutic interventions.   
 
The report by Wen and colleagues contributes to the evidence for dual effects of AMI triggers and 
highlights the need for cautious use of NSAIDs in the context of ARI; clinicians should consider 
interactions with both medical conditions and existing medications when prescribing NSAIDs for 
symptomatic ARI relief. Where NSAID use is deemed necessary, those judged safer from a CVD 
perspective, notably ibuprofen or naproxen, should be used.  The role of antiviral agents such as 
neuraminidase inhibitors was not assessed in the present study, but these should be considered as a 
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treatment option, especially for severely ill patients admitted to hospital with an ARI likely to be due 
to influenza13. In future, better characterisation of the interaction between infections, NSAIDs and 
other genetic, socio-demographic and clinical CVD risk factors and therefore the populations at risk 
will help to inform stratified ARI management. Furthermore, studies of interventions such as 
influenza and pneumococcal vaccinations to reduce the risk of ARIs triggering cardiac events may 
provide findings that influence routine care in the near future.  
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